Navigation Links
BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
Date:11/26/2013

tion correlates with the Mayo endoscopic score for disease severity. IL-6 levels were also significantly reduced (p=0.046) in patients treated with BL-7040, and most patients with reduced cytokine levels showed clinical improvement. 

"These positive results are an extension of the initial positive results of the Phase 2a trial for BL-7040, which showed that this promising drug is both safe and effective in treating ulcerative colitis. In fact, the clinical improvement in this trial was achieved after a relatively short treatment period, which leads us to believe that BL-7040 would have an even stronger beneficial effect after longer treatment duration," said Dr. Kinneret Savitsky, CEO of BioLineRx. "The new results, which show that BL-7040 significantly reduces inflammatory factors, such as neutrophils and cytokines, support BL-7040's mechanism of action – the ability to suppress the specific processes underlying the disease. Crohn's disease and ulcerative colitis, both forms of IBD, are prevalent conditions that affect the quality of life of millions of people across the globe. It is estimated that as many as 1.4 million persons in the United States suffer from these diseases. In addition to discomfort, which can be quite extreme, IBD can cause significant complications, including anemia, abscesses and more. Current treatments are far from satisfactory, and many people stand to benefit from a new and effective treatment for this condition. We believe that the positive results seen throughout the phase 2a study, as well its oral availability, make BL-7040 an attractive potential future treatment option."

About the Phase 2a Study                       
The Phase 2a trial was an open-label, proof-of-concept study to evaluate the efficacy, pharmacodynamics, safety and to
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
2. BioLineRx Reports Third Quarter 2013 Financial Results
3. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
4. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
5. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
6. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
7. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
8. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
9. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
10. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
11. BioLineRx to Present at 15th International Celiac Disease Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (NYSE: RMD ) today announced results for its ... $423.0 million, a 10 percent increase compared to the quarter ... constant currency basis). Net income was $91.2 million, an increase ... 2013. Diluted earnings per share for the quarter were $0.64, ...
(Date:1/22/2015)... , Jan. 22, 2015  Profil Institute for Clinical ... diabetes and obesity, announced today a new textbook,  Translational ... published by Springer, a leading global scientific publisher. ... and illustrate techniques for use in early phase clinical ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) ... by Allergen Source, Product & by End User - Global ... The global allergy diagnostics market is valued at $1,228.58 ... CAGR of 12.67%, to reach $2,230.72 million by 2019. Allergy ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... 13 Stop Aging Now has been ... as one of America,s fastest-growing private companies. Stop ... anti-aging, sells high-quality anti-aging vitamins and supplements. ... ) Stop Aging Now was ...
... Candidate Dan Onorato, along with physicians, nurses, patients, political ... participate in a free public event on Wednesday, October ... will have on the health care industry, cardiovascular care ... Reform Means for You," will take place at the ...
Cached Medicine Technology:Stop Aging Now Named to Prestigious Inc. 5000 List 2Health Care and Community Leaders Discuss the Impact of Health Care Reform in Pennsylvania 2Health Care and Community Leaders Discuss the Impact of Health Care Reform in Pennsylvania 3Health Care and Community Leaders Discuss the Impact of Health Care Reform in Pennsylvania 4
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... 2015 Joan Lunden, award-winning American journalist, ... the upcoming 32nd Annual Miami Breast Cancer Conference ... Resource®, LLC (PER®) , shares that “a fast-growing, virulent” ... if she had not followed up her clean mammogram ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... Palm City, Florida (PRWEB) January 22, 2015 ... use cold therapy machine with patented IsoTube design to treat ... has introduced the most progressive and easy to use ... help treat post-operative and sports related orthopedic and muscle injuries. ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... just 3 fewer grams a day slashed heart disease, death rates ... by just 3 grams a day -- the equivalent of half ... and death in U.S. adults, researchers claim. , According to the ... the New England Journal of Medicine , the projected reductions ...
... , ... "A;" less than 1/4 give secondary schools an "A" , ... and social workers are often the first line of support for children ... disorder and homelessness to depression and bullying all of which can make ...
... Medical Center have found three key factors in a ... studies are a crucial step in developing scientifically sound ... The results from the studies are published in the ... Findings from the pair of studies indicate ...
... , ... levels are associated with a significantly higher risk of relapse attacks in patients with multiple ... from the University of California, San Francisco. , ... (Vocus) January 20, 2010 -- Low vitamin D blood levels are ...
... few miles up are on the rise, , WEDNESDAY, Jan. 20 ... are reporting that springtime ozone levels above western North America are ... from Asia. , The boosts in ozone could make it ... ground level air set by the Clean Air Act, according to ...
... Cigotine, ... is asking its valued customers to continue to support the rights of smokers everywhere, by ... ... Recently, Judge Richard J. Leon of Federal District Court in Washington issued a preliminary injunction ...
Cached Medicine News:Health News:Small Cuts in Salt Intake Spur Big Drops in Heart Trouble 2Health News:Small Cuts in Salt Intake Spur Big Drops in Heart Trouble 3Health News:School Support Lacking for Emotional, Behavioral Issues, say Parents 2Health News:School Support Lacking for Emotional, Behavioral Issues, say Parents 3Health News:School Support Lacking for Emotional, Behavioral Issues, say Parents 4Health News:3 key factors to help children avoid social rejection identified 2Health News:Low Vitamin D Levels are Associated With Greater Risk of Relapse in Childhood-Onset Multiple Sclerosis 2Health News:Low Vitamin D Levels are Associated With Greater Risk of Relapse in Childhood-Onset Multiple Sclerosis 3Health News:Low Vitamin D Levels are Associated With Greater Risk of Relapse in Childhood-Onset Multiple Sclerosis 4Health News:Asian Air May Be Worsening Ozone Over U.S. 2Health News:CIGOTINE Celebrates Federal Ruling Allowing Import and Distribution of E-Cigarettes 2Health News:CIGOTINE Celebrates Federal Ruling Allowing Import and Distribution of E-Cigarettes 3
... isotopic anemia assays feature ... ,pipetting steps for greater ... the processes ,involved in ... benefit to your laboratory ...
... The Zeus Scientific, Inc. ANA Screen ELISA test ... detect anti-nuclear antibodies (ANA) in human sera. When ... system is capable of detecting all ANAs commonly ... DNA (dsDNA), Jo-1, Sm, Sm/RNP, SSA, SSB, and ...
... Concepts manufactures slides that are compatible with ... decrease the number of pipetting steps required ... dilutions on the slides. Ask Immuno Concepts ... these slides. These slide formats are noted ...
... patented HEp-2 cell line that has been ... SS-A/Ro autoantibodies, without affecting the other ANA ... published worldwide on the HEp-2000 ANA substrate, ... when used in place of standard HEp-2 ...
Medicine Products: